Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 267

1.

Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life.

Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group..

Clin Microbiol Infect. 2017 Apr 12. pii: S1198-743X(17)30210-0. doi: 10.1016/j.cmi.2017.04.005. [Epub ahead of print]

PMID:
28412381
2.

Letter: sustained virological response and liver healing.

Rossotti R, Garcia-Fraile Fraile LJ, Baiguera C, Puoti M.

Aliment Pharmacol Ther. 2017 Apr;45(8):1171-1173. doi: 10.1111/apt.13982. No abstract available.

PMID:
28326575
3.

ELITA consensus statements on use of DAAs in liver transplant candidates and recipients.

Belli LS, Duvoux C, Berg T, Strazzabosco M, Fagiuoli S, Khoo S, Pageaux GP, Colle I, Puoti M, Coilly A, Samuel D, Berenguer M; ELITA board members..

J Hepatol. 2017 Mar 18. pii: S0168-8278(17)30140-X. doi: 10.1016/j.jhep.2017.03.006. [Epub ahead of print] Review.

PMID:
28323126
4.

Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2017 Feb 28;12(2):e0172159. doi: 10.1371/journal.pone.0172159. eCollection 2017.

5.

News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.

Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F.

AIDS Rev. 2017 Jan-Mar;19(1):47-53. Review.

PMID:
28182613
6.

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.

Bonora S, Puoti M.

AIDS Rev. 2017 Jan-Mar;19(1):24-34. Review.

PMID:
28182611
7.

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group..

Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20.

PMID:
28105744
8.

Treatment of patients with chronic hepatitis C infection in Lombardia: a report by the Lombardia Hepatitis Network.

Aghemo A, Bruno R, Colombo M, Medagli M, Puoti M, Rizzardini G, Fagiuoli S; Lombardia Hepatitis Network..

Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):17-19.

9.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.

Massimo A, Teti E, Antinori A, Milazzoi L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirianni A, Pennica A, Pasquazzi C, Segala D, Sarmati L; SIMIT (Società Italiana di Malattie Infettivee Tropicali)..

Clin Infect Dis. 2016 Dec 22. pii: ciw846. doi: 10.1093/cid/ciw846. [Epub ahead of print]

PMID:
28011605
10.

Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus.

Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group..

Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4. doi: 10.1016/j.cmi.2016.12.003. Epub 2016 Dec 9.

PMID:
27956268
11.

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.

Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M, Stern JO, Kukolj G, Roehrle M, Aslanyan S, Deng Q, Vinisko R, Mensa FJ, Nelson DR.

Clin Exp Gastroenterol. 2016 Nov 24;9:351-363. eCollection 2016.

12.

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.

Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A; Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord..

HIV Med. 2017 Mar;18(3):171-180. doi: 10.1111/hiv.12411. Epub 2016 Sep 14.

13.

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.

Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, Battegay M, Brockmeyer N, Berenguer J, Morlat P, Obel N, De Wit S, Fätkenheuer G, Zangerle R, Ghosn J, Pérez-Hoyos S, Campbell M, Prins M, Chêne G, Meyer L, Dorrucci M, Torti C, Thiébaut R; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord..

HIV Med. 2017 Jan;18(1):33-44. doi: 10.1111/hiv.12389. Epub 2016 Sep 14.

PMID:
27625009
14.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord..

Clin Infect Dis. 2016 Nov 1;63(9):1245-1253. Epub 2016 Aug 30.

PMID:
27578823
15.

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, Natha M, Zhu Y, Yang J, Kreter B, Brainard DM, Yun C, Carr V, Dore GJ.

Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. Epub 2016 Aug 23.

PMID:
27553375
16.

From current status to optimization of HCV treatment: Recommendations from an expert panel.

Craxì A, Perno CF, Viganò M, Ceccherini-Silberstein F, Petta S; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party..

Dig Liver Dis. 2016 Sep;48(9):995-1005. doi: 10.1016/j.dld.2016.06.004. Epub 2016 Jun 15.

PMID:
27388261
17.

Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.

Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group..

J Antimicrob Chemother. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185. Epub 2016 Jun 5.

PMID:
27272727
18.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015.

Antinori A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Di Biagio A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group..

New Microbiol. 2016 Apr;39(2):93-109. No abstract available.

19.

Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.

Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group..

J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5.

PMID:
26945711
20.

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.

Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group..

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849.

Supplemental Content

Loading ...
Support Center